Biotech

All Articles

OS Treatments refiles $6M IPO to cash HER2 drug, preclinical ADCs

.OS Therapies will certainly list on the NYSE American stock exchange today through a $6.4 million I...

ALX's waning CD47 response price sends out sell spiraling down

.ALX Oncology's period 2 gastric cancer response price has actually damaged. After observing its CD4...

Ionis axes eye disease from intendeds of Roche-partnered possibility after records dissatisfy

.Another of Ionis Pharmaceuticals' essential midphase readouts has disappointed requirements, cuing ...

Biogen's chief executive officer mentioned no dangerous handle 2023. He prepares to become strong

.While Biogen's pharma peers are searching for late-stage possessions with little threat, chief exec...

Instil refills pipe in $2B biobucks manage ImmunOnco

.Instil Biography has actually been actually a biotech in search of a pipeline after it ditched its ...

Biogen walks away from Denali Alzheimer's collab

.Biogen has actually handed back civil rights to a very early Alzheimer's illness program to Denali ...

Takeda touches brand new head people oncology business-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our summary of considerable leadership hirings, shootings a...

Vertex, hammered by AATD once again, loses 2 assets on throw out heap

.Vertex's effort to alleviate an uncommon genetic ailment has attacked one more misfortune. The biot...

Vir gains 3 T-cell engagers coming from Sanofi, gives up 25% of personnel

.Vir Biotechnology's second-quarter earnings record had not been except huge information. The compan...

Galapagos stops CAR-T tissue treatment trial over Parkinsonism instance

.Galapagos has paused enrollment in a trial of a BCMA-directed CAR-T cell therapy, pumping the brake...